Sophia Genetics SA (SOPH): Price and Financial Metrics
SOPH Price/Volume Stats
Current price | $4.93 | 52-week high | $7.37 |
Prev. close | $5.26 | 52-week low | $2.13 |
Day low | $4.93 | Volume | 21,100 |
Day high | $5.21 | Avg. volume | 51,895 |
50-day MA | $4.77 | Dividend yield | N/A |
200-day MA | $3.92 | Market Cap | 321.59M |
SOPH Stock Price Chart Interactive Chart >
Sophia Genetics SA (SOPH) Company Bio
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest SOPH News From Around the Web
Below are the latest news stories about SOPHIA GENETICS SA that investors may wish to consider to help them evaluate SOPH as an investment opportunity.
Hôpital Saint-Louis Implements SOPHiA DDM™ Platform to Further Research of Myeloid DisordersSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation is an expansion of its existing work with SOPHiA GENETICS. |
SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare ConferenceBOSTON and ROLLE, Switzerland, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ: SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PST in San Francisco. Live, listen-only webcasts of this presentation can be accessed by visiting the Investors section of the SOPHiA GENETICS website at ir.sophiagenetics.com. A replay of the webcast will b |
SOPHiA GENETICS Announces Expanded Suite of Liquid Biopsy OfferingsSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced an expanded suite of solutions under SOPHiA DDM™ for Liquid Biopsy. The range of solutions, including MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions, will help progress oncology research and tumor mutation profiling. The rollout of SOPHiA GENETICS' liquid biopsy capabilities demonstrates the company's commitment to developing advanced solutions that empower timely, cri |
SOPHiA GENETICS Announces Expansion of Work with CHU de NîmesSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that it has expanded its work with CHU de Nîmes, a regional and university hospital located in the South of France. The hospital system will use the SOPHiA DDM™ Platform to progress its pharmacogenomics research. |
SOPHiA GENETICS Expands Relationship with Città della Salute e della Scienza di TorinoSOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with the Città della Salute e della Scienza di Torino located in Turin, Italy. The hospital, which used SOPHiA GENETICS after a public tender in 2021 to optimize workflows and support research in the areas of hereditary cancer, neurological disorders, solid tumors, hematology and rare disease, will further expand its usage |
SOPH Price Returns
1-mo | -1.20% |
3-mo | 4.67% |
6-mo | 93.71% |
1-year | 3.79% |
3-year | N/A |
5-year | N/A |
YTD | 4.67% |
2023 | 128.64% |
2022 | -85.39% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...